Skip to main content

Table 4 Multiple comparison test of HDL-C level among treatment duration periods, by sex.

From: Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records

Treatment duration

Female HDL-C (nmol/L)

Male HDL-C (nmol/L)

 

Exam.N

LS mean ± SE

95% CI

p value

Exam.N

LS mean ± SE

95% CI

p value

Baseline

102

1.57 ± 0.04

1.50/1.65

reference

210

1.38 ± 0.04

1.33/1.44

reference

0~3M

53

1.51 ± 0.04

1.42/1.59

0.1087

84

1.40 ± 0.03

1.34/1.47

0.889

3~6M

41

1.56 ± 0.04

1.47/1.64

0.9579

73

1.36 ± 0.03

1.29/1.42

0.8245

6~9M

26

1.45 ± 0.05

1.36/1.55

0.0054*

58

1.37 ± 0.04

1.30/1.44

0.9719

9~12M

15

1.47 ± 0.06

1.36/1.59

0.1423

46

1.36 ± 0.04

1.28/1.44

0.9444

  1. HDL-C: high density lipoprotein cholesterol, Exam N: number of examinations, LS mean: least squares mean, SE: standard error, CI: confidence interval, p value: p value of treatment duration period (compared with baseline, multiple-comparison test: Dunnett-Hsu post-hoc analysis), *: p < 0.05.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840